7 Key Functions of the Food and Drug Administration

The Food and Drug Administration (FDA) is the federal regulatory agency responsible for protecting public health by ensuring the safety, effectiveness, and security of the products that American consumers and patients use daily. For regulated manufacturers — pharmaceutical companies, medical device makers, food producers, dietary supplement manufacturers, cosmetics brands, and tobacco product companies — the FDA’s functions are not background context. They define the regulatory obligations that govern product development, manufacturing, labeling, post-market surveillance, and enforcement exposure.

Understanding what the FDA actually does in each of these areas, and why it does it, is practical knowledge for quality managers, regulatory affairs professionals, and compliance teams. This article covers the seven core FDA functions, the statutory and regulatory basis for each, and what each function means in practice for regulated manufacturers.

What Is the Food and Drug Administration?

History and Statutory Authority

The FDA’s regulatory authority traces to the Pure Food and Drug Act of 1906, passed in response to public alarm over contaminated food and fraudulent patent medicines. The 1906 Act gave the federal government authority to seize adulterated or misbranded food and drug products — establishing the principle that product safety is a federal responsibility, not just a market matter. The agency was formally named the Food and Drug Administration in 1930.

The Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938 significantly expanded the FDA’s authority following the sulfanilamide disaster, in which an improperly tested drug formulation killed more than 100 people. The FD&C Act required pre-market safety review of new drugs for the first time and established the framework that underlies most of the FDA’s current authority. Subsequent legislation has extended the FDA’s jurisdiction to medical devices (Medical Device Amendments of 1976), generic drugs (Drug Price Competition and Patent Term Restoration Act of 1984), food safety modernization (Food Safety Modernization Act of 2011), tobacco products (Family Smoking Prevention and Tobacco Control Act of 2009), and cosmetics (Modernization of Cosmetics Regulation Act of 2022).

Mission and Organizational Structure

The FDA’s mission is to protect and promote public health through science-based regulation. The agency operates through a structure of product-specific centers: the Center for Drug Evaluation and Research (CDER) oversees pharmaceutical products; the Center for Devices and Radiological Health (CDRH) oversees medical devices; the Center for Food Safety and Applied Nutrition (CFSAN) oversees food, dietary supplements, and cosmetics; the Center for Biologics Evaluation and Research (CBER) oversees biological products including vaccines, blood, and gene therapies; and the Center for Tobacco Products (CTP) oversees tobacco. Each center develops the regulations, guidances, and enforcement actions within its product jurisdiction.

For regulated manufacturers, the relevant center determines which regulations apply, which reviewers evaluate submissions, and which investigators conduct inspections. Understanding which FDA center governs your product category — and what that center’s current enforcement priorities are — is foundational regulatory intelligence for any quality or regulatory affairs function.

7 Key Functions of the FDA

1. Food Safety and Regulation

The FDA oversees the safety of most of the domestic food supply — essentially everything except meat, poultry, and egg products, which fall under USDA jurisdiction. This includes domestic food production, processing, and distribution, as well as imported food products, which account for a substantial and growing share of the US food supply.

The Food Safety Modernization Act (FSMA), signed into law on January 4, 2011, is the most significant overhaul of US food safety law since the FD&C Act of 1938. FSMA shifted the FDA’s approach from responding to foodborne illness outbreaks after the fact to preventing them through preventive controls. Key FSMA rules require food manufacturers to implement Hazard Analysis and Risk-Based Preventive Controls (HARPC) — hazard analysis, preventive controls, monitoring, corrective actions, and verification — documented in a food safety plan. These requirements are analogous in structure to GMP-based quality systems in pharmaceutical and device manufacturing, but they apply to the food supply chain.

Food recalls are a central enforcement mechanism under FDA authority. The FDA can request voluntary recalls and, under FSMA, has mandatory recall authority for certain food products. For regulated food manufacturers, the FDA’s ability to access records, conduct inspections, and issue public alerts means that quality system documentation — production records, supplier qualification records, corrective action records — is both a regulatory requirement and a front-line defense against enforcement action.

2. Drug Regulation and Approval

The FDA’s drug approval function is one of its most resource-intensive and consequential responsibilities. The Center for Drug Evaluation and Research (CDER) reviews new drug applications (NDAs) for small-molecule prescription drugs, over-the-counter medications, abbreviated new drug applications (ANDAs) for generic drugs, and certain well-characterized therapeutic biologics that were transferred to CDER jurisdiction. The Center for Biologics Evaluation and Research (CBER) independently reviews biologics license applications (BLAs) for vaccines, blood components, cellular therapies, gene therapies, and other biological products that remain under CBER’s jurisdiction. The standard for approval in both centers is substantial evidence of safety and effectiveness from adequate and well-controlled clinical investigations — a standard that typically requires years of development and clinical testing before a product reaches the market.

The drug development pathway moves through preclinical studies, an Investigational New Drug (IND) application before human testing begins (governed by 21 CFR Part 312), and then Phase I (safety and dose), Phase II (preliminary efficacy and safety), and Phase III (confirmatory efficacy and safety) clinical trials before the NDA or BLA is submitted. Accelerated approval pathways — Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review — are available for drugs addressing serious conditions with unmet medical needs, allowing earlier market access in exchange for post-market confirmatory commitments.

Post-market drug safety is monitored through the FDA Adverse Event Reporting System (FAERS), through which healthcare professionals, manufacturers, and consumers report adverse drug reactions. Manufacturers have mandatory reporting obligations under 21 CFR Part 314 for NDAs and 21 CFR Part 600 for biological products. Post-market safety findings can result in labeling changes, Risk Evaluation and Mitigation Strategies (REMS), or, in serious cases, market withdrawal. For pharmaceutical quality teams, the connection between CAPA systems, complaint management, and adverse event reporting obligations is direct: a complaint or nonconformance that meets the reporting threshold triggers a regulatory submission with specified timelines. Commercial drug manufacturing quality operations must satisfy the Current Good Manufacturing Practice requirements for finished pharmaceuticals codified under 21 CFR Parts 210 and 211 — the regulations governing facilities, equipment, production controls, laboratory controls, packaging, labeling, and records that FDA investigators evaluate during CGMP inspections.

3. Medical Device Oversight

The Center for Devices and Radiological Health (CDRH) regulates medical devices under a risk-based classification system established by the Medical Device Amendments of 1976. Devices are classified as Class I (low risk, general controls), Class II (moderate risk, special controls, typically requiring 510(k) premarket notification), or Class III (high risk, requiring Premarket Approval — PMA — with clinical evidence of safety and effectiveness). The 21st Century Cures Act of 2016 left this three-class structure intact but amended the statutory definition of a medical device to exclude certain digital health and software functions from FDA jurisdiction, and created the Breakthrough Devices Program to accelerate review of certain novel, high-priority devices.

The 510(k) pathway — the most common route to market for medical devices — allows a manufacturer to demonstrate substantial equivalence to a legally marketed predicate device. Substantial equivalence requires the same intended use and either the same technological characteristics as the predicate, or different technological characteristics that do not raise new questions of safety and effectiveness. The De Novo pathway provides a route for novel low-to-moderate risk devices without a suitable predicate, establishing a new device type and classification that can serve as a predicate for future 510(k)s.

Once on the market, device manufacturers are subject to quality management requirements under QMSR (21 CFR Part 820, effective February 2, 2026), Medical Device Reporting (MDR) obligations under 21 CFR Part 803, and the FDA’s postmarket surveillance program. MDR reporting timeframes require manufacturers to report device-related deaths, serious injuries, or malfunctions likely to cause or contribute to a death or serious injury if they recurred to FDA within 30 calendar days of becoming aware, and within 5 work days for events that require remedial action to prevent an unreasonable risk of substantial harm to public health. For device quality teams, the MDR obligation is a direct link between the complaint management and CAPA systems and the regulatory submission calendar.

4. Tobacco Product Regulation

The Family Smoking Prevention and Tobacco Control Act of 2009 granted the FDA — through the Center for Tobacco Products (CTP) — the authority to regulate the manufacture, marketing, and sale of tobacco products. This authority covers traditional cigarettes, smokeless tobacco, cigars, hookah tobacco, and electronic nicotine delivery systems (e-cigarettes, vaping products), which were brought under FDA jurisdiction through a 2016 deeming rule.

New tobacco products and modified risk tobacco products require FDA authorization before they can be marketed. New tobacco product applications (PMTA — Premarket Tobacco Application) require manufacturers to demonstrate that their product is appropriate for the protection of the public health — a standard that considers effects on both users and non-users, including youth. The FDA has used its authority to restrict flavored tobacco products and to require graphic health warnings on cigarette packaging and advertising.

For manufacturers of tobacco products, the FDA’s authority includes facility registration, product listing, Good Manufacturing Practice requirements, and inspection authority comparable to what applies in pharmaceutical and device manufacturing. The quality management implications are significant: tobacco product manufacturers subject to FDA oversight must maintain documentation, complaint records, and production controls that will withstand FDA inspection.

5. Risk Assessment and Public Health Protection

The FDA’s risk assessment function underpins its regulatory decision-making across all product categories. Before the FDA takes a regulatory action — approving a product, requiring a labeling change, initiating a recall, or issuing a warning letter — it conducts a benefit-risk assessment that weighs the product’s demonstrated benefits against its identified risks in the context of the available therapeutic or dietary alternatives.

For regulated manufacturers, the FDA’s risk framework has direct operational implications. Post-market safety surveillance — adverse event monitoring, complaint trend analysis, signal detection — is a regulatory obligation precisely because the FDA’s premarket review is necessarily limited by the data available at the time of approval. Post-market experience generates safety signals that the benefit-risk calculus must incorporate. A quality system that generates high-quality post-market safety data — through robust complaint management, structured investigations, and timely CAPA closure — is both a regulatory compliance mechanism and a risk management asset.

The FDA also coordinates risk response with other federal agencies. During foodborne illness outbreaks, the FDA works with the CDC and USDA to identify sources and implement protective measures. During public health emergencies, the FDA has authority to issue Emergency Use Authorizations (EUAs) for unapproved products or unapproved uses of approved products — a mechanism that was extensively used during the COVID-19 pandemic for vaccines, diagnostics, and therapeutics.

6. Oversight of Dietary Supplements and Cosmetics

Dietary supplements occupy a distinctive regulatory position under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Unlike drugs, dietary supplements do not require premarket approval — manufacturers are responsible for ensuring their products are safe before marketing them. The FDA can take action against unsafe or mislabeled supplements after they are on the market, but the burden of proof for a safety action lies with the FDA, not the manufacturer. New Dietary Ingredient (NDI) notifications are required for ingredients introduced to the market after October 15, 1994, providing FDA with advance notice of novel supplement ingredients.

The regulatory landscape for cosmetics changed significantly with the Modernization of Cosmetics Regulation Act (MoCRA), signed into law on December 29, 2022. MoCRA was the first major update to FDA’s cosmetics authority since 1938. Key MoCRA requirements include mandatory facility registration and product listing for cosmetics manufacturers, mandatory adverse event reporting for serious adverse events (with a 15-business-day reporting timeline for serious adverse events), substantiation of safety for cosmetic products, and enhanced record-keeping requirements. Cosmetics manufacturers who previously operated under a light-touch regulatory framework must now maintain quality documentation and adverse event reporting processes more comparable to those in other FDA-regulated industries.

For quality professionals in the supplement and cosmetics industries, the practical implications of DSHEA and MoCRA are substantial. Supplement manufacturers must have documented processes for ingredient verification, product testing, labeling review, and complaint handling that can withstand FDA inspection under 21 CFR Part 111 (Current Good Manufacturing Practice for dietary supplements). Cosmetics manufacturers must now build the facility registration, adverse event reporting, and product safety documentation infrastructure that MoCRA requires.

7. Advancing Public Health Through Guidance, Education, and Research

Beyond its enforcement and review functions, the FDA shapes regulated industry practice through guidance documents, public health campaigns, and its engagement with the scientific and research communities. FDA guidance documents — while not legally binding in the way regulations are — represent the FDA’s current thinking on how to comply with statutory and regulatory requirements, and they are treated as authoritative by regulated manufacturers, their legal counsel, and FDA investigators conducting inspections.

For regulated manufacturers, FDA guidances are operational documents. When the FDA issues guidance on a topic relevant to your product category — data integrity, process validation, quality metrics, computer system validation — it communicates what FDA investigators will look for when they inspect your facility. Tracking, reading, and implementing guidance documents is a core function of any effective regulatory affairs or quality team.

The FDA also conducts and supports research through its own laboratories and through collaboration with academic institutions and other federal agencies. Its Center for Devices and Radiological Health operates device evaluation laboratories. Its National Center for Toxicological Research conducts safety research on food ingredients, drugs, and environmental contaminants. The FDA’s Oncology Center of Excellence coordinates cancer product review across the agency’s centers, accelerating the development and review of cancer drugs, biologics, and devices. These research functions are not separate from the FDA’s regulatory mission — they generate the scientific basis for regulatory standards and review decisions.

How the FDA Collaborates with Other Agencies and International Bodies

Domestic Interagency Coordination

The FDA does not operate in isolation from the broader federal public health and regulatory infrastructure. Its most significant domestic partners are the Centers for Disease Control and Prevention (CDC), the U.S. Department of Agriculture (USDA), and the Environmental Protection Agency (EPA). CDC-FDA collaboration is most visible during foodborne illness investigations, when the two agencies combine outbreak surveillance data with product traceback investigations to identify the source. USDA-FDA coordination governs the regulatory boundary between meat, poultry, and egg products (USDA) and all other food products (FDA). EPA-FDA coordination addresses pesticide residue tolerances in food, where EPA sets the tolerance and FDA enforces it.

For regulated manufacturers, interagency enforcement coordination means that a single quality event — a foodborne illness cluster, a contaminated ingredient — can trigger regulatory response from multiple agencies simultaneously. Quality systems that maintain complete, accurate, and readily accessible records are better positioned to respond to multi-agency investigations than those relying on manual reconstruction.

International Regulatory Cooperation

The FDA participates in international regulatory harmonization through several channels. The International Council for Harmonisation (ICH) develops internationally harmonized technical guidelines for pharmaceutical development, quality, safety, and efficacy — guidelines that the FDA has adopted as the basis for many of its pharmaceutical regulations and guidances. The International Medical Device Regulators Forum (IMDRF) develops frameworks for medical device regulatory convergence, and the FDA is an active participant. Bilateral mutual recognition agreements with regulatory partners including the European Medicines Agency (EMA), Health Canada, and other national authorities allow for reliance on each other’s inspection findings, reducing duplication for manufacturers selling into multiple markets.

For manufacturers seeking regulatory approval in multiple markets, international harmonization means that a quality system built to satisfy FDA requirements under QMSR, ICH Q10, and ICH Q7 will substantially overlap with the requirements of other major regulatory bodies — but not completely. Understanding where FDA requirements diverge from EU GMP, ICH guidelines, or other national standards is a core competency for regulatory affairs teams managing multi-market product portfolios.

What FDA Oversight Means for Regulated Manufacturers

The FDA’s seven functions are not abstract regulatory categories for the quality and compliance teams responsible for meeting them. Each function has direct operational implications for how a regulated manufacturer designs its quality management system, documents its processes, trains its personnel, and responds when things go wrong.

Food manufacturers operating under FSMA preventive controls rules need documented food safety plans, hazard analyses, and preventive control monitoring records that are designed for FDA inspection from day one, not assembled before an audit. Pharmaceutical manufacturers need adverse event reporting workflows that connect complaint intake, investigation, and regulatory submission within the required timeframes. Medical device manufacturers need CAPA systems that generate the documented root cause and effectiveness verification evidence that both QMSR and MDR reporting obligations require. Cosmetics manufacturers now need adverse event reporting and product safety substantiation programs that MoCRA mandates.

In each case, the quality management system is the operational infrastructure through which FDA regulatory obligations are fulfilled. A quality system that was designed generically — without specific accommodation for the FDA functions that govern its product category — will generate compliance gaps that are visible to FDA investigators during inspections and that create enforcement exposure. Understanding what the FDA does, and why, is the prerequisite for building quality systems that actually satisfy the regulatory obligations that each FDA function imposes.  The most operationally significant enforcement instruments for regulated manufacturers are FDA Form 483 (Notice of Inspectional Observations) and Warning Letters. An FDA inspection typically concludes with the investigator issuing a Form 483 listing each observed condition that, in the investigator’s judgment, represents a violation of applicable requirements. Manufacturers must respond to Form 483 observations promptly and substantively — typically within 15 business days — with a corrective action plan addressing each observation. An inadequate response, or unresolved observations from a prior inspection, can escalate to a Warning Letter, which is a formal agency finding of significant regulatory violations that becomes part of the public record and can affect product approvals, import alerts, and supplier relationships. For quality teams at regulated manufacturers, inspection readiness — the state of having documentation, records, and corrective action systems that can withstand FDA investigator scrutiny at any time — is not a periodic audit preparation exercise. It is the baseline operating standard.

Conclusion

The FDA’s seven core functions — food safety, drug regulation, medical device oversight, tobacco regulation, risk assessment, supplement and cosmetics oversight, and public health research and education — define the regulatory landscape that every company selling FDA-regulated products in the United States must navigate. The agency’s statutory authority is broad, its enforcement mechanisms are consequential, and its expectations for documented quality systems are both rigorous and specific.

For quality managers, regulatory affairs professionals, and compliance teams at regulated manufacturers, understanding the FDA’s functions is not background reading — it is foundational context for every decision about how to design a quality system, what records to maintain, how to respond to adverse events, and how to prepare for inspection. The FDA’s guidances, regulations, and enforcement actions are the operating environment within which regulated manufacturing quality systems must perform.

eLeaP’s QMS platform is built to support the quality management obligations that FDA oversight imposes — connecting CAPA, complaint management, document control, supplier quality, and training in a single validated system. For more information on eLeaP’s capabilities for FDA-regulated manufacturers, visit quality.eleapsoftware.com.